| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From GERMEN,*
INSERM EMI-0011,
and INSERM U492,
Université Paris XII
Val-De-Marne, Créteil, France
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
Cancer cell invasion involves both ECM proteolysis and cell migration.1,2 High tumor expression of uPAR and uPA is associated with poor prognosis of breast cancer.13 High PAI-1 levels also represent a strong and independent marker of cancer invasiveness and metastatic spreading,13,14 an unexpected finding if one considers that PAI-1 anti-proteolytic activity should potently inhibit cancer invasion.1 The paradox was confirmed by the report that cancer invasion and neovascularization are abolished in PAI-1-deficient mice, and can be restored by local induction of PAI-1 expression.15 In this study, PAI-1 immunoreactivity was mainly detected in peritumoral host stroma, a finding consistent with overexpression of PAI-1 at the periphery of invasive breast cancer.16
In addition to their involvement in proteolysis, the uPA system components exert nonproteolytic roles operative in adhesion and migration of various cell types.9,17-21 Implication of PAI-1 in cell migration was initially considered through its interplay with VN. Indeed, PAI-1 competes with VN cellular ligands, ie, ß-integrins and uPAR.9 According to the cell type and the migration assay used, cell migration on/through VN was either inhibited17,18 or promoted9,19 by addition of PAI-1. We have recently studied the implication of PAI-1 in cell migration through its interactions with both uPAR-bound uPA and LRP. We showed that myogenic cell motility was critically dependent on integrity of the [uPAR:uPA:PAI-1:LRP] complex, both cell migration and membrane ruffling activity being abolished by truncated uPA (ATF) unable to bind PAI-1.22 These results were in keeping with a mechanical role of the uPA system23 in which the [uPAR:uPA:PAI-1:LRP] complex could transiently bridge the cell membrane to ECM.22 Ability of PAI-1 to both decrease its affinity for matrix VN and increase its affinity for endocytic receptors in response to uPA binding9,10 suggests that it may represent a key molecule in the rapid attachment/disattachment events occurring at the cell leading edge that are required for migration.24
To investigate if and how PAI-1 is implicated in breast cancer cell migration in vitro, and to discriminate the respective role of cancer and host-derived PAI-1, we performed migration assays on uncoated and PAI-1-coated surfaces. Results indicate that matrix PAI-1 can behave as a migration accelerator for cancer cells that strongly express uPA system components, providing a clue to the breast cancer PAI-1 paradox.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Culture media were from Life Technologies (Paisley, UK). Culture plastics, fibronectin (FN), VN, Matrigel, FACS permeabilizing solution, anti-CD29-PE monoclonal antibody (mAb), anti-CD51/CD61-fluorescein isothiocyanate (FITC) mAb, IgG1-PE, and IgG1-FITC were from Becton Dickinson (Bedford, MA). Cell dissociation solution, aprotinin, GRGDTP, Fast Red were from Sigma Chemical Co. (St. Louis, MO). Blocking anti-VN mAb was from Biosource (Camarillo, CA). Blocking anti-integrin ß1 mAb (clone P4C10) was from Chemicon international (Temecula, CA). Control mouse IgGs (0.5 mg/ml) and rabbit Ig (5 mg/ml) were from Vector Laboratories (Burlingame, CA). Goat anti-mouse Ig-FITC (1.8 mg/ml), goat anti-mouse Ig-rhodamine (1.8 mg/ml), and goat anti-rabbit Ig-rhodamine (2 mg/ml) were from Coulter (Fullerton, CA). Active recombinant PAI-1 no. 1095, HMw uPA no. 124, ATF n0. 126, mAb against uPAR no. 3932 (0.5 mg/ml), uPA no. 3689 (0.5 mg/ml), and PAI-1 no. 3780 (0.5 mg/ml) used for labeling experiments, blocking mAb against uPAR no. 3936 and PAI-1 no. 3783 for inhibitory assays were from American Diagnostica (Greenwich, CT). Wild-type PAI-1, anti-LRP (clone 8G1, 0.775 mg/ml), and anti-gp330 (clone 1H2, 0.2 mg/ml) mAbs were generously provided by D. A. Lawrence and D. K. Strickland (Rockville, MD), polyclonal anti-VLDL-R (5.57 mg/ml) antibodies and RAP (receptor-associated protein) were provided by A. Christensen and A. Nykjaer (Aarhus, Denmark), and peptides P25 and P36 were provided by H. A. Chapman (Boston, MA).
Cell Culture
MCF7-AZ, MCF7/6, and MDA-MB-231 breast cancer cell lines were cultured as previously described.25,26 Two MDA-MB-231 clonal cell lines, isolated by end-point dilution and with divergent expressions of the uPA system, were chosen for further studies. In all experiments, cells were harvested using cell dissociation solution.
Flow Cytometry
Cells were treated with FACS permeabilizing solution, incubated with primary antibodies (1/10), further incubated with fluorescent secondary antibodies (1/100), and fixed with paraformaldehyde. Integrin labeling was performed according to the manufacturer’s instructions. Controls were performed using isotypic Ig. A minimum of 5000 cells was counted in each assay. Fluorescence intensity was measured using a Coulter EPICS XL Flow Cytometry System. Percent positive cells was determined according to the marker approach using the population gate described in Current Protocols in Cytometry.27 The marker approach is best suited for single or double indirect labelings according to the same reference.
Immunofluorescence
Cells were fixed by paraformaldehyde, incubated with anti-LRP (30 µg/ml) mAb for 1 hour, washed with phosphate-buffered saline (PBS), then incubated with goat anti-mouse-rhodamine (1/100) antibodies for 1 hour and washed with PBS. Slides were further incubated with either anti-uPAR or anti-uPA (40 µg/ml) or anti-PAI-1 (20 µg/ml) mAbs, washed with PBS, then incubated with goat anti-mouse-FITC (1/100) antibodies, and washed with PBS. To label F-actin, fixed cells were incubated with rhodamine phalloidin (1 µg/ml) for 30 minutes. Controls, including incubation with mouse IgG, showed no labeling. Cells were observed with a Zeiss 100 neofluar lens.
Immunohistochemistry
Immunohistochemical expression of the uPA system and the endocytic receptors was evaluated as previously described28 in 16 breast ductal in situ carcinomas, with or without microinvasion [grade III (n = 6), grade II (n = 6), grade I (n = 4)[rqsb], and 15 invasive ductal carcinomas of various grades [grade III (n = 8), grade II (n = 4), grade I (n = 3)].29 Sections were microwaved in 100 mmol/L Tris-HCl, pH 8 (4 x 5 minutes) for uPAR, and 10 mmol/L citrate, pH 6 (3 x 5 minutes) for PAI-1 detection. Proteinase XXIV (10 minutes) was used for uPA detection. Slides were treated by bovine serum albumin 3% for 2 hours, incubated with primary antibodies (against uPAR, 40 µg/ml; uPA, 40; PAI-1, 20; LRP, 10; VLDLR, 50; gp330, 20) at 4°C overnight, further treated using LSAB2 kit and stained with Fast Red. Controls were performed using isotypic Ig.
Cell Attachment Assay
Ninety-six-wells plates were coated for 1 hour and 30 minutes with 40 µg/ml of PAI-1 diluted in PBS and saturated with bovine serum albumin 1% for 30 minutes. Cells (30,000 per well) were incubated for 2 hours at 37°C, washed, fixed, and stained with crystal violet. Optical density was read at 570 nm. Optical density obtained in bovine serum albumin-coated wells was subtracted. When used, effectors were added to the cells at time of seeding. In some experiments, HMw uPA (5 µg/ml) was added 30 minutes before seeding.
Two-Dimensional Migration Assay
This assay was modified from that previously described.30 Cells were seeded into a glass cylinder deposited on a Petri dish. At subconfluence, the cylinder was removed, and cells were gently washed and allowed to migrate in serum-free medium for 6 hours at 37°C. Strictly similar results were obtained when MDA-MB-231 cells were seeded at high density (to be used immediately at subconfluence) and shortly grown without serum (3 to 15 hours) before cylinder removal, or when MDA-MB-231 cells were seeded into the cylinder, allowed to grow in presence of serum until subconfluence (several days), and subjected to washings before starting the migration assay in serum-free conditions. The area occupied by the cells was recorded using a charge-coupled device camera attached to an inverted microscope and quantified with the Zeiss KS-300 imaging system. The radius of the area occupied by the cells, considered as a disk, was calculated. The migration score was expressed as the radius calculated after a 6-hour incubation time beyond the initial radius and was given in µm. The measurement represents net changes in the whole-cell population and not single cell movements. Increase of the area was not because of cell proliferation, because the total cell number did not vary statistically during the whole experiment. Cell migration was also tested on supports coated with FN, VN, or PAI-1. Although active recombinant PAI-1 (no. 1095) has a given half-life of more than 500 hours at 25°C, its ability to bind uPA after a 5-day incubation was confirmed using uPA-FITC (not shown). When used, effectors were added to the cells at the beginning of the incubation at 37°C.
Three-Dimensional Migration Assay
For invasion assay,31 inserts with 8-µm pores for 24-well plates were coated on their upper aspect with 50 µg/insert of Matrigel containing PAI-1 (0 to 10 µg/ml). Cells (2 x 105) were added in the upper chamber and incubated 20 hours in serum-free medium. Cells emigrated to the lower aspect of the membrane were fixed, stained with crystal violet, and counted manually at x20 magnification (5 fields per insert).
Statistical Analysis
Results are means ± SEM of experiments run in triplicate and
performed using three different cultures. The Mann Whitney and
Student’s t-tests were used. P values are
indicated in figures as follows: *, P < 0.05; **,
P 
0.01; ***, P 0.005.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
In vivo expression of uPAR was not observed in ductal
in situ carcinoma (0 of 16) but was observed in zones of
diffuse infiltration of invasive ductal carcinoma (11 of 15),
regardless of their grade. uPAR immunostaining was observed in cancer
cells, where it was particularly strong in isolated invasive cells
remote from the bulk of the tumor (Figure 1A)
. It was also observed in spindle
stromal cells at the invasion margin and in macrophages in both
neoplastic and nonneoplastic breast tissue. uPA (Figure 1B)
and PAI-1
(Figure 1C)
immunostainings were detected in both cancer and stromal
cells of invasive ductal carcinoma (15 of 15) and ductal in
situ carcinoma (11 of 16), cancer cell expression being invariably
stronger in invasive ductal carcinoma than in ductal in situ
carcinoma. Stromal PAI-1 expression was particularly strong in spindle
cells in an immediate vicinity of invasive tumor cells (Figure 1C)
.
Endocytic receptors were expressed in both cancer and stromal cells,
regardless of staging. Virtually all cancer cells expressed VLDL-R (not
shown), occasional cancer cells expressed LRP (Figure 1D)
, and none
expressed gp330 (not shown).
|
. In contrast to LRP the expression of
which correlated positively with invasiveness (P
< 0.005), that of VLDL-R correlated negatively with invasiveness
(P < 0.05), whereas gp330 was virtually not
expressed. The respective percentage of positive noninvasive MCF7-AZ
cells was: uPAR, 33 ± 7%; uPA, 48 ± 2.2; PAI-1, 45 ±
0.8; LRP, 17 ± 1.4; VLDL-R, 36 ± 5; gp330, 0.3; that of
moderately invasive MCF7/6 cells was: uPAR, 40 ± 10.3%; uPA,
50 ± 14.2; PAI-1, 55 ± 3.0; LRP, 25 ± 3.8; VLDL-R,
15 ± 3; gp330, 0.5; that of most invasive MDA-MB-231 cells was:
uPAR, 48 ± 6.7%; uPA, 64 ± 6.7; PAI-1, 65 ± 4.3;
LRP, 55 ± 8.1; VLDL-R, 0.7; gp330, 2.
|
.
|
Migration of the three cell lines on plastic correlated positively
with their invasiveness: the distance covered in 6 hours was 31.5
± 5.2, 50.4 ± 8.2, and 91.6 ± 8.9 µm for MCF7-AZ,
MCF7/6, and MDA-MB-231 cells, respectively (P <
0.001) (Figure 4
, inset).
|
. However, anti-uPAR mAb that block uPA
binding to uPAR inhibited migration proportionally to invasiveness
(inhibition by 59.2%, 80.8, and 84.3 for MCF7-AZ, MCF7/6, and
MDA-MB-231 cells, respectively, all P < 0.005) (Figure 4)
. Similarly, ATF (amino-terminal fragment of uPA), which is unable to
bind PAI-1 but competes with uPA for uPAR binding, also inhibited
migration [by 43.8% (P < 0.01), 77.7%
(P < 0.005), and 79.4%
(P < 0.005), respectively], as did anti-PAI-1
mAb (by 47.6%, 66.7%, and 76.2%, all P < 0.005)
(Figure 4)
. Receptor-associated protein (RAP), which inhibits the
binding to LDL-receptor family members, also inhibited migration (by
50% (P < 0.05), 76.2%
(P < 0.005), and 77.7%
(P < 0.005), respectively) (Figure 4)
. This
effect was likely because of LRP inhibition as the strongest inhibition
was observed on MDA-MB-231 cells that lack gp330 and VLDL-R.
Blocking anti-VN mAb inhibited migration in inverse proportion to
invasiveness (by 81.7%, 65.8%, and 54.1% for MCF7-AZ, MCF7/6, and
MDA-MB-231 cells, respectively, all P < 0.005), as did
GRGDTP peptide, that inhibits integrin binding to ECM proteins [100%,
68.2% (P < 0.005), and 66.7%
(P < 0.01), respectively] (Figure 4)
.
To investigate the role of the complex formed by uPAR, uPA, PAI-1, and LRP in cell migration, we first assessed attachment capacities of cancer cells on PAI-1.
Invasive Cells Can Attach to a PAI-1 Coat
MDA-MB-231 cells attached to a PAI-1 coat in a dose-dependent way
(P < 0.05); this attachment at 0.37 µmol/L
was twofold less efficient on PAI-1 than on VN
(P < 0.05) (Figure 5A)
.
|
. Removing uPA from uPAR by acid
washing37
prevented cell attachment to PAI-1
(P < 0.01) (Figure 5B)
. Addition of ATF to
acid-washed cells at time of seeding did not allow attachment
(P < 0.01) whereas in the same conditions,
addition of uPA restored cell attachment up to the control value
(Figure 5B)
. Similarly, saturation of the PAI-1 coat with uPA before
seeding allowed acid-washed cells to attach, whereas untreated cells
did not attach (Figure 5B)
. These results indicate that the complexed
uPAR, uPA, and PAI-1 molecules link cell membrane to the support.
Interestingly, LRP was also required for full cell attachment to PAI-1
as RAP inhibited attachment by 70% (P < 0.01)
(Figure 5B)
. This suggested that the cell-to-support molecular link was
dynamic. Consistently, cells seeded on PAI-1 showed striking
morphological changes. These changes consisted in marked filopodia
formation whereas no stress fibers were observed (Figure 5C)
. They
differed from the changes observed in cells seeded on VN that mainly
showed stress fiber formation and less filopodia than cells seeded on
PAI-1 (Figure 5C)
. We then assessed the migrating capacities of cancer
cells on PAI-1-coated surfaces.
PAI-1-Enriched Environment Markedly Accelerates Migration of Invasive Cells
Migration of all cancer cell lines was significantly increased on
immobilized PAI-1 as compared to uncoated surfaces. But the effect of
PAI-1 was more pronounced in invasive cells, the covered distances
being increased by 37.8% (P < 0.01), 57.9%
(P < 0.005), and 70.2%
(P < 0.005) for MCF7-AZ, MCF7/6, and MDA-MB-231
cells, respectively (Figure 6A)
. Both ATF
and RAP dramatically inhibited cell migration on immobilized PAI-1: ATF
decreased migration by 76.4%, 90.6%, and 83.8%, and LRP by 77%,
90%, and 93.3%, respectively (all P < 0.005) (Figure 6A)
. MDA-MB-231 cell migration rate on PAI-1 was 1.5-fold and 15-fold
higher than on FN and VN, respectively (P <
0.05 and P < 0.005) (Figure 6B)
. As cells can produce
ECM molecules during the assay, we evaluated involvement of VN and
integrins in migration on PAI-1. Neither did anti-VN mAb, GRGDTP,
anti-integrin ß1 mAb (that inhibited cell migration on FN by 96%),
nor P25, a peptide inhibiting the lateral interaction between uPAR and
integrins38
affect invasive cell attachment or migration
on PAI-1 (not shown).
|
. According to Their Expression of uPAR, uPA, PAI-1, and LRP, Invasive Cell Clones Use Either Integrins or the uPA System to Migrate
Expression of the uPA system components by MDA-MB-231 cells was
heterogeneous, showing two or three different subpopulations (Figure 2)
. End-point dilution technique provided two clonal cell lines, called
MDAlow and MDAhigh in
respect with their markedly divergent expression of uPA system
components. The respective percentage of positive cells were: for uPAR
17 ± 2.5 versus 59 ± 4.2%
(P < 0.005), for uPA 27 ± 2.3
versus 60 ± 2% (P < 0.05),
for PAI-1 41 ± 4.2 versus 71 ± 1.4%
(P < 0.01), for LRP 38 ± 3
versus 68 ± 0.6% (P < 0.01),
for gp3302 versus 4%, for VLDL-R and 0.3 versus
1% (Figure 7A)
. Invasion assays through
Matrigel indicated that MDAhigh subclone was
threefold more invasive than the parental MDA-MB-231 cell line and that
MDAlow subclone was twofold less invasive than
MDA-MB-231 cells (not shown), a finding consistent with previous
studies indicating a correlation between expression of uPA system
components and cell invasiveness.33,35,36
|
. Conversely
MDAhigh cell migration was poorly affected by
integrin inhibition (GRGDTP inhibition, 27%; NS) and strongly
inhibited by both ATF (71%, P < 0.01) and RAP (62%,
P < 0.01) (Figure 7B)
.
The two cell lines exhibited markedly divergent migration rates on
PAI-1, MDAhigh cells migrating at very high
velocity on this support (Figure 7C)
(P <
0.005). They had similar migration rates on FN (Figure 7C)
, a finding
in keeping with a similarly high (99%) expression of ß1 integrin
(Figure 7A)
. In addition, the two clones had different migration rates
on VN (Figure 7C)
, despite a similar and moderate (14 ± 5%)
expression of 
ß3, the main integrin for VN (Figure 7A)
. VN
accelerating effect on MDAlow was mild (migration
rate less than twofold that on plastic and similar to that on FN)
whereas PAI-1 accelerating effect on MDAhigh was
marked (migration rate more than fivefold that on plastic and more than
twofold that on FN) (Figure 7C)
.
Finally, the two cell lines showed divergent reorganizations of their
actin cytoskeleton; on VN, MDAlow cells became
polarized whereas MDAhigh cells remained rounded
(Figure 7D)
. Conversely, on PAI-1, MDAlow cells
did not polarize whereas MDAhigh cells developed
a polarized migrating phenotype (Figure 7D)
.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Both dynamic links of cell membrane to ECM and signal transduction occur at the leading edge of migrating cells.24 The uPA system components were detected at the leading edge of invasive cells and at the tip of filopodia. Interrelations of the uPA system with molecules that regulate lamellipodia cytoskeletal organization, such as myosin light chain kinase,39 rac-1, and RhoA,40 have been recently described. Association of the uPA system with membrane-ruffling activity was also mentioned,41 and, indeed, microcinematography has previously shown that ATF suppresses filopodia, membrane-ruffling activity, and motility of myogenic cells.22
In the present study, we used an in vitro model with minimal implication of the VN-dependent migration systems to delineate the role of PAI-1 per se. Admittedly, in vivo, PAI-1 interacts with ECM macromolecules, such as VN, and might participate in cell migration through a coordinated combination of molecular events. These may include: 1) high-affinity ligation of cell membrane uPAR-bound uPA to matrix PAI-1; 2) PAI-1 detachment from ECM; 3) subsequent internalization of the complex through LRP ligation and, possibly, stable links of integrins to ECM. Myriads of transient sequences of membrane to ECM attachment/disattachment at the leading edge could well participate in membrane-ruffling activity, and groping of filopodia along ECM aimed at cell guidance through selection of appropriate sites for cell attachment.22 This view is supported by the evidence that PAI-1 increases both filopodia formation, migration, and invasion of very invasive cancer cells. Interestingly, uPAR is co-localized with chemokine (CK) receptors at the leading edge of leukocytes and other fast-migrating cells42,43 and numerous studies have identified chemotactic roles for uPA and for uPAR.41,44-47 Chemotaxis/haptotaxis relies on sensing the extracellular concentration of appropriate ligands and coupling of chemo-attractant receptor occupation to cytoskeletal changes leading to cell polarization.48 Although structurally unrelated to CKs and their receptors, the uPA system has the characteristic properties of a CK system: 1) as CKs,49,50 PAI-1 is adsorbed on ECM; 2) as CK receptors,43,51 uPAR-bound uPA is localized at the leading edge and filopodia of migrating cells; 3) similarly to CK-enriched environments,52,53 PAI-1-enriched environment boosts cell migration; 4) as CK/CK receptor complexes,54,55 the uPAR-bound uPA:PAI-1 complex is rapidly internalized; 5) as CK receptors,42,56 uPAR/adapter may transduce intracellular signals implying heterotrimeric G proteins.41
Invasive capacities of breast cancer cell lines paralleled migration
velocity, expression of the uPA system components and of LRP,
implication of the [uPAR:uPA:PAI-1:LRP] complex in migration, and
promigratory effects of PAI-1. This was in keeping with the marked
membrane ruffling of invasive breast cancer cells.25
Fast-migrating cells do not develop strong cell-matrix interactions, as
assessed by lack of both focal contact and stress fiber
formation.48
Most invasive MDA-MB-231 cells harbored such
a phenotype when seeded on PAI-1; in contrast, they developed stress
fibers when seeded on VN. This was indicative of various populations
among MDA-MB-231 cells. These included a clonal population
(MDAhigh) that expressed high amounts of the uPA
system components and used the uPA system preferentially to integrins
for their migration, and another clonal population
(MDAlow) showing weak expression of the uPA
system and using the integrin-mediated migration pathway. Admittedly,
the two clonal cell lines may differ in more ways than just the markers
analyzed. Nevertheless, the two clones had migration rates on PAI-1 and
FN in accordance with their expression of uPA system components and
ß1 integrins, respectively. In contrast, they had different migration
rates on VN, despite a similar expression of ß3, the main VN
ligand. This was consistent with previous reports on PAI-1 effects on
adhesion/migration on VN, that operate through modulation of PAI-1:VN
interactions.9,17-19
However, PAI-1:VN interplay could
not be directly instrumental in the fast cell migration observed on
PAI-1 coat. Moreover, on MDAhigh cells, the PAI-1
accelerating effect markedly exceeded the VN decelerating effect. This
suggests that, when cells displaying the appropriate uPA system
expression maneuver in a PAI-1-enriched milieu, the promigratory effect
directly operated by matrix PAI-1 overcomes the inhibitory effects of
PAI-1. This view was supported by the accelerating effect of matrix
PAI-1 observed in the three-dimensional invasion assay.
Breast cancer tissue expression of the uPA system mainly included uPAR expression by cancer cells in invasive, but not in situ, tumors, and expression of uPA and PAI-1 by both cancer and stromal cells that parallel tumor aggressiveness.14,16,28 Endocytic receptors were also expressed by both cancer and stromal cells.28,57 Taken together with our in vitro experiments, these results could suggest that invasive cancer cells may use the uPA system in multiple ways in vivo. At the initial stage of breast cancer, when PAI-1, but not uPAR, is expressed in and around the tumor, PAI-1 anti-proteolytic activity may inhibit cancer cell invasion. At the invasion stage, cancer cells displaying uPAR at their surface,28 can exert directional proteolysis of ECM that is counteracted by the presence of increasing levels of PAI-1 in the environment. The finding of divergent cancer clones in MDA-MB-231 cells indicates that, subsequently to mutations, the tumor cells may use different strategies to migrate depending on the availability of the relevant ligands in the cell environment. Thus, eventually, some cells might take advantage of the high amounts of PAI-1 present in the environment to migrate, using a novel function of the [uPAR:uPA:PAI-1:LRP] complex. This could explain the apparent paradox of poor prognosis of invasive breast cancers expressing high PAI-1 levels.
|
Acknowledgements |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
Footnotes |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Supported by the Association pour la Recherche contre le Cancer, by the Institut Garches (to B. C.), by a INSERM/CNRS grant "adhesion cellules-materiaux," and by the Ministère de la Recherche, Université Paris XII (to G. B. M.).
Accepted for publication October 8, 2001.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
nß3 binding to vitronectin. Nature 1996, 383:441-443[Medline]
This article has been cited by other articles:
 |
|
 |
|
  Y. Fan, G. P. Boivin, E. S. Knudsen, D. W. Nebert, Y. Xia, and A. Puga The Aryl Hydrocarbon Receptor Functions as a Tumor Suppressor of Liver Carcinogenesis Cancer Res., January 1, 2010; 70(1): 212 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Song, Y. Li, J. Lee, A. L. Schwartz, and G. Bu Low-Density Lipoprotein Receptor-Related Protein 1 Promotes Cancer Cell Migration and Invasion by Inducing the Expression of Matrix Metalloproteinases 2 and 9 Cancer Res., February 1, 2009; 69(3): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Lillis, L. B. Van Duyn, J. E. Murphy-Ullrich, and D. K. Strickland LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies Physiol Rev, July 1, 2008; 88(3): 887 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dedieu, B. Langlois, J. Devy, B. Sid, P. Henriet, H. Sartelet, G. Bellon, H. Emonard, and L. Martiny LRP-1 Silencing Prevents Malignant Cell Invasion despite Increased Pericellular Proteolytic Activities Mol. Cell. Biol., May 1, 2008; 28(9): 2980 - 2995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Maquerlot, S. Galiacy, M. Malo, C. Guignabert, D. A. Lawrence, M.-P. d'Ortho, and G. Barlovatz-Meimon Dual Role for Plasminogen Activator Inhibitor Type 1 as Soluble and as Matricellular Regulator of Epithelial Alveolar Cell Wound Healing Am. J. Pathol., November 1, 2006; 169(5): 1624 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. De Taeye, T. Novitskaya, L. Gleaves, J. W. Covington, and D. E. Vaughan Bone Marrow Plasminogen Activator Inhibitor-1 Influences the Development of Obesity J. Biol. Chem., October 27, 2006; 281(43): 32796 - 32805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lafuste, C. Sonnet, B. Chazaud, P. A. Dreyfus, R. K. Gherardi, U. M. Wewer, and F.-J. Authier ADAM12 and {alpha}9{beta}1 Integrin Are Instrumental in Human Myogenic Cell Differentiation Mol. Biol. Cell, February 1, 2005; 16(2): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sato, T. Tanaka, K. Maemura, T. Uchiyama, H. Sato, T. Maeno, T. Suga, T. Iso, Y. Ohyama, M. Arai, et al. The PAI-1 Gene as a Direct Target of Endothelial PAS Domain Protein-1 in Adenocarcinoma A549 Cells Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 209 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Chazaud, C. Sonnet, P. Lafuste, G. Bassez, A.-C. Rimaniol, F. Poron, F.-J. Authier, P. A. Dreyfus, and R. K. Gherardi Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth J. Cell Biol., December 8, 2003; 163(5): 1133 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Orr, C. A. Elzie, D. F. Kucik, and J. E. Murphy-Ullrich Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration J. Cell Sci., July 15, 2003; 116(14): 2917 - 2927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stefansson and D. A. Lawrence Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration Sci. Signal., July 1, 2003; 2003(189): pe24 - pe24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, J. M. Knisely, W. Lu, L. M. McCormick, J. Wang, J. Henkin, A. L. Schwartz, and G. Bu Low Density Lipoprotein (LDL) Receptor-related Protein 1B Impairs Urokinase Receptor Regeneration on the Cell Surface and Inhibits Cell Migration J. Biol. Chem., October 25, 2002; 277(44): 42366 - 42371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Palmieri, J. W. Lee, R. L. Juliano, and F. C. Church Plasminogen Activator Inhibitor-1 and -3 Increase Cell Adhesion and Motility of MDA-MB-435 Breast Cancer Cells J. Biol. Chem., October 18, 2002; 277(43): 40950 - 40957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Vaughan PAI-1 and Cellular Migration: Dabbling in Paradox Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1522 - 1523. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Providence, L. A. White, J. Tang, J. Gonclaves, L. Staiano-Coico, and P. J. Higgins Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene J. Cell Sci., January 10, 2002; 115(19): 3767 - 3777. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
